Theramab LLC Report issue

For profit Phase 2
Founded: Russian Federation (2013)
Status: Defunct (2022)

Organization Overview

First Clinical Trial
2013
NCT01885624
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

tgn-1412 (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Neoplasms (Phase 1)

Psoriasis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 1